NasdaqGS:ALMSPharmaceuticals
A Look At Alumis (ALMS) Valuation After ONWARD Phase 3 Psoriasis Data And FDA Filing Plans
Why the latest ONWARD data matters for Alumis stock
Alumis (ALMS) is in focus after releasing detailed Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib in moderate to severe plaque psoriasis, paired with plans for a U.S. FDA New Drug Application this year.
The data set highlights skin clearance rates, quality of life measures, and a 24 week safety profile in more than 1,700 patients. It has been featured in a late breaking oral session at the 2026 American Academy of Dermatology...